Orthobiologics in the knee

Q4 Medicine Orthopaedics and Trauma Pub Date : 2023-06-01 DOI:10.1016/j.mporth.2023.03.002
Gemma E. Toland, Navnit S. Makaram, Ran Atzmon, Joseph P. Donohue, Iain R. Murray
{"title":"Orthobiologics in the knee","authors":"Gemma E. Toland,&nbsp;Navnit S. Makaram,&nbsp;Ran Atzmon,&nbsp;Joseph P. Donohue,&nbsp;Iain R. Murray","doi":"10.1016/j.mporth.2023.03.002","DOIUrl":null,"url":null,"abstract":"<div><p><span>Orthobiologics therapies in the knee are a relatively new and rapidly evolving field that use biological treatments to help repair and regenerate damaged tissues in the knee. These therapies include stem cells, platelet-rich plasma (PRP) and other growth factors to promote healing and reduce inflammation. The use of orthobiologics has gained considerable interest in recent years for the treatment of a variety of musculoskeletal pathologies. As ‘natural’ treatments, they represent an attractive option for patients and surgeons that can be used in conjunction with traditional surgical procedures for augmentation, or in isolation as an alternative to surgery in a minimally-invasive manner. While orthobiologics therapies hold great promise in the treatment of knee conditions, there have been a variety of challenges to the widespread use of these therapies, including ambiguity in nomenclature, leading to confusion among consumers and providers, biologic heterogeneity, regulatory challenges and a lack of well-designed level one studies evaluating these agents that adequately report variables critical to outcome or assess purity/potency of treatments delivered. This article will provide an overview of the current orthobiologic options for the treatment of </span>orthopaedic pathologies in the knee, as well as a discussion surrounding the current evidence and associated controversies.</p></div>","PeriodicalId":39547,"journal":{"name":"Orthopaedics and Trauma","volume":"37 3","pages":"Pages 143-153"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orthopaedics and Trauma","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877132723000222","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Orthobiologics therapies in the knee are a relatively new and rapidly evolving field that use biological treatments to help repair and regenerate damaged tissues in the knee. These therapies include stem cells, platelet-rich plasma (PRP) and other growth factors to promote healing and reduce inflammation. The use of orthobiologics has gained considerable interest in recent years for the treatment of a variety of musculoskeletal pathologies. As ‘natural’ treatments, they represent an attractive option for patients and surgeons that can be used in conjunction with traditional surgical procedures for augmentation, or in isolation as an alternative to surgery in a minimally-invasive manner. While orthobiologics therapies hold great promise in the treatment of knee conditions, there have been a variety of challenges to the widespread use of these therapies, including ambiguity in nomenclature, leading to confusion among consumers and providers, biologic heterogeneity, regulatory challenges and a lack of well-designed level one studies evaluating these agents that adequately report variables critical to outcome or assess purity/potency of treatments delivered. This article will provide an overview of the current orthobiologic options for the treatment of orthopaedic pathologies in the knee, as well as a discussion surrounding the current evidence and associated controversies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
膝关节矫形器
膝关节原位生物疗法是一个相对较新且快速发展的领域,它使用生物治疗来帮助修复和再生膝关节受损组织。这些疗法包括干细胞、富含血小板的血浆(PRP)和其他生长因子,以促进愈合和减少炎症。近年来,正生物制剂在治疗各种肌肉骨骼疾病方面引起了人们的极大兴趣。作为“自然”治疗,它们对患者和外科医生来说是一个有吸引力的选择,可以与传统的手术程序结合使用,也可以单独使用,作为微创手术的替代方案。虽然正交生物疗法在治疗膝关节疾病方面有很大的前景,但这些疗法的广泛使用面临着各种挑战,包括命名上的模糊性,导致消费者和提供者之间的混淆,生物异质性,监管方面的挑战,以及缺乏精心设计的一级研究来评估这些药物,这些研究能够充分报告对结果至关重要的变量或评估所提供治疗的纯度/效力。这篇文章将概述目前用于治疗膝关节整形病理的矫形生物学选择,以及围绕当前证据和相关争议的讨论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Orthopaedics and Trauma
Orthopaedics and Trauma Medicine-Orthopedics and Sports Medicine
CiteScore
1.00
自引率
0.00%
发文量
57
期刊介绍: Orthopaedics and Trauma presents a unique collection of International review articles summarizing the current state of knowledge and research in orthopaedics. Each issue focuses on a specific topic, discussed in depth in a mini-symposium; other articles cover the areas of basic science, medicine, children/adults, trauma, imaging and historical review. There is also an annotation, self-assessment questions and a second opinion section. In this way the entire postgraduate syllabus will be covered in a 4-year cycle.
期刊最新文献
Editorial Editorial Board Trauma to the lower cervical spine (sub-axial or C3–C7) in adults Cauda equina syndrome Injuries of the thoracic spine and the thoracolumbar junction
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1